DK0980252T3 - Terapier til akut nyresvigt - Google Patents

Terapier til akut nyresvigt

Info

Publication number
DK0980252T3
DK0980252T3 DK98919715T DK98919715T DK0980252T3 DK 0980252 T3 DK0980252 T3 DK 0980252T3 DK 98919715 T DK98919715 T DK 98919715T DK 98919715 T DK98919715 T DK 98919715T DK 0980252 T3 DK0980252 T3 DK 0980252T3
Authority
DK
Denmark
Prior art keywords
renal failure
acute renal
therapies
risk
treatment
Prior art date
Application number
DK98919715T
Other languages
Danish (da)
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0980252T3 publication Critical patent/DK0980252T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98919715T 1997-05-05 1998-05-05 Terapier til akut nyresvigt DK0980252T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4561997P 1997-05-05 1997-05-05
EP98919715A EP0980252B1 (en) 1997-05-05 1998-05-05 Therapies for acute renal failure
PCT/US1998/003197 WO1998050060A1 (en) 1997-05-05 1998-05-05 Therapies for acute renal failure

Publications (1)

Publication Number Publication Date
DK0980252T3 true DK0980252T3 (da) 2005-01-31

Family

ID=21938961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98919715T DK0980252T3 (da) 1997-05-05 1998-05-05 Terapier til akut nyresvigt

Country Status (11)

Country Link
US (2) US20100105621A1 (https=)
EP (1) EP0980252B1 (https=)
JP (2) JP5033276B2 (https=)
AT (1) ATE278414T1 (https=)
AU (1) AU743510B2 (https=)
CA (1) CA2289123A1 (https=)
DE (1) DE69826854T2 (https=)
DK (1) DK0980252T3 (https=)
ES (1) ES2226125T3 (https=)
PT (1) PT980252E (https=)
WO (1) WO1998050060A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612046B2 (en) 2000-01-31 2009-11-03 Uwe Waldemar Rothenpieler Method for treating kidney disorders
ES2351957T3 (es) * 2000-01-31 2011-02-14 Uwe Waldemar Rothenpieler Pax2 para tratar trastornos del riñón.
EP1407770B1 (en) * 2001-06-26 2013-06-05 Takeda Pharmaceutical Company Limited Tgf-beta superfamily production/secretion promoter
US20050272649A1 (en) * 2002-08-28 2005-12-08 Hruska Keith A Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
RU2282899C2 (ru) * 2004-01-09 2006-08-27 ГОУ ВПО Омская Государственная Медицинская Академия Способ моделирования инфекции мочевой системы
EP3147296A1 (en) * 2005-11-14 2017-03-29 Merial, Inc. Gene therapy for renal failure
US8025881B2 (en) 2006-07-21 2011-09-27 Chugai Seiyaku Kabushiki Kaisha BMP antibodies and methods of treating kidney disease using the same
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
KR101870246B1 (ko) * 2014-02-07 2018-06-22 토루 미야자키 신질환의 예방 또는 치료제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
DE69031939T2 (de) 1989-03-28 1998-09-10 Genetics Institute, Inc., Cambridge, Mass. Osteoinduktive zusammensetzungen
JPH06500991A (ja) 1990-05-16 1994-01-27 ジェネティックス・インスティテュート・インコーポレイテッド 骨および軟骨誘導蛋白質
JPH0426624A (ja) 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
JPH05509086A (ja) 1990-06-22 1993-12-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
WO1992015323A1 (en) 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
DE69233559T2 (de) * 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
EP0601129B1 (en) 1991-08-30 2000-11-15 Creative Biomolecules, Inc. Morphogenic protein screening method
ATE192931T1 (de) * 1991-08-30 2000-06-15 Creative Biomolecules Inc Morphogen-induzierte modulation von entzündlichen antworten
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
JPH07509720A (ja) 1992-07-31 1995-10-26 クリエイティブ　バイオモレキュルズ，インコーポレイテッド モルフォゲン強化栄養組成物
EP0653942B2 (en) * 1992-07-31 2007-03-07 Curis, Inc. Morphogen-induced nerve regeneration and repair
ATE287949T1 (de) 1992-07-31 2005-02-15 Stryker Corp Löslicher komplex morphogener proteine und zusammensetzungen davon
ES2114073T3 (es) 1992-09-16 1998-05-16 Creative Biomolecules Inc Regeneracion del higado inducida por morfogenes.
JPH08503198A (ja) 1992-11-03 1996-04-09 クリエイティブ バイオモレキュルズ，インコーポレイテッド Ｏｐ−３誘導形態形成
JPH08510446A (ja) 1993-03-04 1996-11-05 クリエイティブ バイオモレキュルズ，インコーポレイテッド 組換え骨形成タンパク質を生成するための方法および組成物
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
JPH09509141A (ja) * 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド Ｉｇｆ‐ｉおよびｉｇｆｂｐ‐３を投与することによる腎臓疾患処置の方法
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
KR20000064752A (ko) * 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
CA2289123A1 (en) 1998-11-12
AU743510B2 (en) 2002-01-24
JP5033276B2 (ja) 2012-09-26
PT980252E (pt) 2005-01-31
DE69826854T2 (de) 2006-02-02
ATE278414T1 (de) 2004-10-15
JP2009286802A (ja) 2009-12-10
EP0980252A1 (en) 2000-02-23
EP0980252B1 (en) 2004-10-06
JP2001523264A (ja) 2001-11-20
ES2226125T3 (es) 2005-03-16
WO1998050060A1 (en) 1998-11-12
US8748378B2 (en) 2014-06-10
DE69826854D1 (de) 2004-11-11
US20100105621A1 (en) 2010-04-29
US20110257093A1 (en) 2011-10-20
AU7244398A (en) 1998-11-27

Similar Documents

Publication Publication Date Title
ATE277629T1 (de) Morphogenische behandlung des chronischen nierenversagens
DK0980252T3 (da) Terapier til akut nyresvigt
Mulder et al. Treatment of nonhealing diabetic foot ulcers with a platelet‐derived growth factor gene‐activated matrix (GAM501): Results of a Phase 1/2 trial
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
DK1238658T3 (da) Understöttet afgivelse af et aktivt middel under anvendelse af et implanterbart system
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
NO982436D0 (no) Apparat for oppvarming av blod
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
FI956078A0 (fi) Järjestelmä veren virusten inaktivoimiseksi
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
NO865068D0 (no) System, fremgangsmaate og apparat til fraksjonering av blod in situ.
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE69228997D1 (de) Menschliche il-3-varianten
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
EP0960117A4 (en) ON FIBROBLASTS GROWTH FACTOR HOMOLOGICAL FACTORS (FHFs) AND METHOD OF APPLICATION
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
TR199900596T2 (xx) Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�.
ATE238796T1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
EP0990441A4 (en) MEDICINES FOR TREATING DIABETIC NEPHROSIS
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
FI952170A7 (fi) Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
FR2764389B1 (fr) Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
ATE232738T1 (de) Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung